FDMT241018C50000
- 0.05
- 0.000.00%
4D Molecular Therapeutics Newsroom
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
4D Molecular Therapeutics Analyst Ratings
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $82
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $79
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
4D Molecular Therapeutics (FDMT) Receives a Buy From RBC Capital
The Latest Analyst Ratings For 4D Molecular Therapeutics
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), 4D Molecular Therapeutics (FDMT) and Cullinan Management (CGEM)
Buy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising Pipeline
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)
Analysts Conflicted on These Healthcare Names: Senseonics Holdings (SENS), PepGen Inc. (PEPG) and 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
Buy Rating for 4D Molecular Therapeutics: Promising Future Based on Product Efficacy and Strategic Growth Prospects
4D Molecular Therapeutics Analyst Ratings
RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $40 Price Target